you are concerned [1%):65 years) as compared to young adults. Although the C max is increased 16-40%, the increase in mean AUC is approximately 30%, and can be at least partially attributed to decreased renal clearance in the elderly. Elimination half-life is only slightly (~20%) prolonged in the elderly. These differences are not considered clinically significant. (See PRECAUTIONS: Geriatric Use .) In patients with reduced renal function, the half-life of ciprofloxacin is slightly prolonged and dosage adjust-ments may be required. (See DOSAGE AND ADMINISTRATION .) In preliminary studies in patients with stable chronic liver cirrhosis, no significant changes in ciprofloxacin pharmacokinetics have been observed. However, the kinetics of ciprofloxacin in patients with acute hepatic insufficiency have not been fully elucidated. Following a single oral dose of 10 mg/kg ciprofloxacin suspension to 16 children ranging in age from 4 months to 7 years, the mean C max was 2.4 mg/mL (range: 1.5 - 3.4 mg/mL) and the mean AUC was 9.2 ug*h/mL (range: 5.8 - 14.9 ug*h/mL). There was no apparent age-dependence, and no notable increase in C max or AUC upon multiple dosing (10 ug/kg TID). In children with severe sepsis who were given intravenous ciprofloxacin (10 mg/kg as a 1-hour infusion), the mean C max was 6.1 ug/mL (range: 4.6 - 8.3 ug/mL) in 10 children less than 1 year of age; and 7.2 ug/mL (range: 4.7 - 11.8 ug/mL) in 10 children between 1 and 5 years of age. The AUC values were 17.4 ug*h/mL (range: 11.8 - 32.0 ug*h/mL) and 16.5 ug*h/mL (range: 11.0 - 23.8 ug*h/mL) in the respective age groups. These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of pediatric patients with various infections, the predicted mean half-life in children is approximately 4 - 5 hours, and the bioavailability of the oral suspension is approximately 60%. Drug-drug Interactions: The potential for pharmacokinetic drug interactions between ciprofloxacin and theophylline, caffeine, cyclosporins, phenytoin, sulfonylurea glyburide, metronidazole, warfarin, probenecid, and piperacillin sodium has been evaluated. (See PRECAUTIONS: Drug Interactions .) MICROBIOLOGY Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. The mechanism of action of fluoroquinolones, including ciprofloxacin, is different from that of penicillins, cephalosporins, aminoglycosides, macrolides, and tetracyclines; therefore, microorganisms resistant to these classes of drugs may be susceptible to ciprofloxacin and other quinolones. There is no known cross-resistance between ciprofloxacin and other classes of antimicrobials. In vitro resistance to ciprofloxacin develops slowly by multiple step mutations. Ciprofloxacin is slightly less active when tested at acidic pH. The inoculum size has little effect when tested in vitro . The minimal bactericidal concentration (MBC) generally does not exceed the minimal inhibitory concentration (MIC) by more than a factor of 2. Ciprofloxacin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section of the package insert for CIPRO I.V. (ciprofloxacin for intravenous infusion). Aerobic gram-positive microorganisms Enterococcus faecalis (Many strains are only moderately susceptible.) Staphylococcus aureus (methicillin-susceptible strains only) Staphylococcus epidermidis (methicillin-susceptible strains only) Staphylococcus saprophyticus Streptococcus pneumoniae (penicillin-susceptible strains) Streptococcus pyogenes Aerobic gram-negative microorganisms Citrobacter diversus Citrobacter freundii Enterobacter cloacae Escherichia coli Haemophilus influenzae Haemophilus parainfluenzae Klebsiella pneumoniae Moraxella catarrhalis Morganella morganii Proteus mirabilis Proteus vulgaris Providencia rettgeri Providencia stuartii Pseudomonas aeruginosa Serratia marcescens Ciprofloxacin has been shown to be active against Bacillus anthracis both in vitro and by use of serum levels as a surrogate marker (see INDICATIONS AND USAGE and INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). The following in vitro data are available, but their clinical significance is unknown. Ciprofloxacin exhibits in vitro minimum inhibitory concentrations (MICs) of 1 ug/mL or less against most (>/= 90%) strains of the following microorganisms; however, the safety and effectiveness of ciprofloxacin intravenous formulations in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials. Aerobic gram-positive microorganisms Staphylococcus haemolyticus Staphylococcus hominis Streptococcus pneumoniae (penicillin-resistant strains) Aerobic gram-negative microorganisms Acinetobacter Iwoffi Aeromonas hydrophila Campylobacter jejuni Edwardsiella tarda Enterobacter aerogenes Klebsiella oxytoca Legionella pneumophila Neisseria gonorrhoeae Pasteurella multocida Salmonella enteritidis Salmonella typhi Shigella boydii Shigella dysenteriae Shigella flexneri Shigella sonnei Vibrio cholerae Vibrio parahaemolyticus Vibrio vulnificus Yersinia enterocolitica Most strains of Burkholderia cepacia and some strains of Stenotrophomonas maltophilia are resistant to ciprofloxacin as are most anaerobic bacteria, including Bacteroides fragilis and Clostridium difficile. Susceptibility Tests Dilution Techniques: Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method 1 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of ciprofloxacin powder. The MIC values should be interpreted according to the following criteria: For testing aerobic microorganisms other than Haemophilus influenzae , and Haemophilus parainfluenzae a : MIC (ug/mL) Interpretation] Antibiotics 101 Everything you need to know about antibiotics: List of Common Antibiotics & Types Antibiotics & Drinking Alcohol - Is it Safe? Antibiotics For UTI - What Are My Options? FDA Consumer Updates Depression: FDA-Approved Medications May Help Dealing with ADHD: What You Need to Know Making Decisions for Your Health: Getting the Info You Need FDA: Cutting-Edge Technology Sheds Light on Antibiotic Resistance More FDA updates along with your
incidentally Cipro I.V. many people
EmoticonEmoticon